医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EpimAb Biotherapeutics Announces IND Filing for EMB01 in China and the US

2018年09月14日 AM11:00
このエントリーをはてなブックマークに追加


 

SHANGHAI

EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, announced today that it has filed an IND for its most advanced therapeutic development candidate EMB01. The applications were simultaneously submitted to the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) in China to investigate the treatment of solid tumors with EpimAb’s novel bispecific antibody.

“Advancing our first compound into the clinic just three years after founding the company is a significant and transformational milestone for EpimAb,” commented Chengbin Wu, PhD, CEO and founder of EpimAb Biotherapeutics. “This achievement proves that our FIT-Ig® technology delivers bispecific antibodies with drug-like properties and manufacturing efficiency that can rapidly be advanced into clinical trials. We are now eager to learn how these novel drug candidates can impact patients’ lives.”

EMB01 is a bispecific antibody based on EpimAb’s proprietary FIT-Ig® (Fabs-In-Tandem Immunoglobulin) technology to generate bispecific molecules with superior properties. EMB01 simultaneously targets two receptors, which are widely expressed on cancer cells, EGFR and cMET, with a unique and synergistic mechanism and has shown significant and long-lasting activity in multiple preclinical solid tumor models. EpimAb initiated formal preclinical development in May 2017 and since then successfully completed all requirements for IND filing.

While EMB01 is progressing towards the clinic, EpimAb is advancing several biologics creating a proprietary pipeline based on its FIT-Ig® platform. These earlier-stage assets are focused on immuno-oncology approaches in areas of high medical need in cancer.

About EpimAb Biotherapeutics, Inc.

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. For further information, please visit www.epimab.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005374/en/

CONTACT

Contact
EpimAb Biotherapeutics
Dr. Stephan
Lensky, COO/CBO
Direct: +49 152 2610 7621
E-Mail: Stephan.lensky@epimab.com
or
Media
Inquiries

Mario Brkulj or Amanda Houlihan
Direct: +49 175
5711562
Main: +49 89 24243494 or +1 781 235 3060
E-Mail: mbrkulj@macbiocom.com
or ahoulihan@macbiocom.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CDISC Releases Therapeutic Area User Guide to Bring Clarity to Data for Colorectal Cancer Research
  • While China Investigates Marriott’s Dirty Rooms, UNITE HERE Offers Briefing with Housekeepers
  • Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc
  • アルヴォテックと富士製薬が日本でバイオシミラーを開発・商業化するための独占提携契約を締結
  • Alvotech与富士制药缔结排他性伙伴关系,在日本从事生物类似物的开发和商业化